Table 1.
Current delivery systems for disease treatment.
| Drug | Delivery System | Target | Disease | Reference |
|---|---|---|---|---|
| 17-AAG | PLGA | Heat shock protein 90(Hsp90) | UC/CAC | [3] |
| 6-gingerol/ 6-shogaol | Ginger-derived exosomes | TNF-α/IL-6/IL-1β/IL-10/IL-12 | IBD | [91] |
| PLGA/PLA-PEG-FA | [103] | |||
| MTX | Grapefruit-derived exosomes | Macrophage | IBD | [88] |
| Dox | Ginger-derived exosomes/ Ginger-derived exosomes combined with FA | Cellular DNA | CAC | [109] |
| siRNA-CD98 | Ginger-derived exosomes | Epithelial/Macrophage | UC | [117] |
| JSI-124 | Grapefruit-derived exosomes/Grapefruit-derived exosomes combined with FA | Stat3 | Brain tumor | [70] |
| Dtxl | PLGA | Microtubule | Tumor | [105] |
| CPT | Synthetic nanoparticles | Epithelial | CAC | [113] |
| Cy3-siRNA | Termed thioketal nanoparticles (TKNs) | TNF-α | IBD | [118] |
| ASO | Amphoteric liposomes | CD40 | IBD | [58] |
| Indocyanine green (ICG) | Aloe-derived exosomes | Melanoma cell | Melanoma | [119] |
| MiR-21 inhibitor and chemotherapeutics | Engineered exosomes | Cellular DNA | CAC | [120] |
| RAGE-binding peptide (RBP) | Engineered exosomes | Cytokine assays in macrophage cells | Lung inflammation | [121] |